Conference Coverage

VIDEO: No major malformations ascribed to bisphosphonate use in pregnancy


 

AT THE EULAR 2016 CONGRESS

References

The results of the study fall in line with those from the two major previous controlled studies on 24 women (Reprod Toxicol. 2006 Nov;22:578-9) and 21 women (Bone. 2009 Mar;44:428-30). Another series of 10 bisphosphonate-exposed pregnancies described 2 malformations, including 1 ventricular septal defect and 1 kidney and cardiac malformation (Autoimmun Rev. 2010 Jun;9:547-52). Another single case report described a neonate with bilateral talipes equinovarus (J Bone Miner Res. 2004 Oct;19:1742-5). A literature review of 78 cases of bisphosphonate exposure during or prior to pregnancy reported three malformations (Hormones [Athens]. 2011 Oct-Dec;10:280-91).

The study is ongoing and continues to collect data on the follow-up of children, Mr. Sokal said.

The study had no specific funding, and none of the investigators had disclosures to report.

jevans@frontlinemedcom.com

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Pages

Recommended Reading

Denosumab better at building bone than zoledronic acid
MDedge Endocrinology
High-dose vitamin D increases fall risk in study of 200 patients
MDedge Endocrinology
Denosumab boosts BMD in kidney transplant recipients
MDedge Endocrinology
Sleep duration linked with gestational weight gain
MDedge Endocrinology
Romosozumab, coming ACR guidelines mark recent high points in osteoporosis
MDedge Endocrinology
Getting a leg up on bone comorbidities in lupus
MDedge Endocrinology
Antisclerostin osteoporosis drugs might worsen or unmask rheumatoid arthritis
MDedge Endocrinology
Early estrogen likely prevents bone fractures in Turner syndrome
MDedge Endocrinology
One-time AMH level predicts rapid perimenopausal bone loss
MDedge Endocrinology
VIDEO: Romosozumab bested teriparatide in hip BMD transitioning from bisphosphonates
MDedge Endocrinology